VYGR insider filings

Voyager Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen VYGR transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Carter Todd Alfred — Chief Scientific Officer1——2
Swartz Robin — President1——2

Recent insider filings — Voyager Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2026-11-034Swartz Robin — PresidentGrant/award (A): 68,250 @ $0 · Grant/award (A): 318,500 (derivative) @ $0EDGAR
2026-11-034Carter Todd Alfred — Chief Scientific OfficerGrant/award (A): 33,000 @ $0 · Grant/award (A): 154,000 (derivative) @ $0EDGAR
2026-06-114MACKEY CATHERINE J — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114Hyman Steven — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114Vitale Nancy — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114Onyia Jude — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114Colon Grace — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114Higgins Michael J — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114PIERCE GLENN — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114GERAGHTY JAMES A — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-114SCANGOS GEORGE A — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-04-034Shiferman Gregory L. — SVP and General CounselGrant/award (A): 50,000 @ $0EDGAR
2026-04-034Sandrock Alfred — President and CEO, DirectorSale (S): 11,511 @ $3.87EDGAR
2026-02-264Swartz Robin — COO & CBOSale (S): 6,458 @ $3.77EDGAR
2026-02-264Jorgensen Nathan D. — Chief Financial OfficerSale (S): 4,668 @ $3.77EDGAR
2026-02-264Carter Todd Alfred — Chief Scientific OfficerSale (S): 4,174 @ $3.76EDGAR
2026-02-264Sandrock Alfred — President and CEO, DirectorSale (S): 14,197 @ $3.79EDGAR
2026-02-204Swartz Robin — COO & CBOSale (S): 3,882 @ $3.44EDGAR
2026-02-204Carter Todd Alfred — Chief Scientific OfficerSale (S): 3,301 @ $3.44EDGAR
2026-02-204Sandrock Alfred — President and CEO, DirectorSale (S): 11,732 @ $3.41EDGAR
2026-02-114Swartz Robin — COO & CBOSale (S): 4,569 @ $3.85EDGAR
2026-02-114Carter Todd Alfred — Chief Scientific OfficerSale (S): 3,525 @ $3.85EDGAR
2026-02-114Sandrock Alfred — President and CEO, DirectorSale (S): 12,192 @ $3.78EDGAR
2026-02-104Ferguson Toby — Chief Medical OfficerGrant/award (A): 45,000 @ $0 · Grant/award (A): 210,000 (derivative) @ $0EDGAR
2026-02-104Carter Todd Alfred — Chief Scientific OfficerGrant/award (A): 33,000 @ $0 · Grant/award (A): 154,000 (derivative) @ $0EDGAR
2026-02-104Swartz Robin — COO & CBOGrant/award (A): 45,000 @ $0 · Grant/award (A): 210,000 (derivative) @ $0EDGAR
2026-02-104Jorgensen Nathan D. — Chief Financial OfficerGrant/award (A): 32,250 @ $0 · Grant/award (A): 150,500 (derivative) @ $0EDGAR
2026-02-104Sandrock Alfred — President and CEO, DirectorGrant/award (A): 86,250 @ $0 · Grant/award (A): 402,500 (derivative) @ $0EDGAR
2026-01-084Shiferman Gregory L. — SVP and General CounselGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-10-074Jorgensen Nathan D. — Chief Financial OfficerSale (S): 7,666 @ $4.78EDGAR
2025-08-204Ferguson Toby — Chief Medical OfficerSale (S): 19,000 @ $3.73EDGAR
2025-06-044Vitale Nancy — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044Onyia Jude — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044MACKEY CATHERINE J — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044Hyman Steven — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044Colon Grace — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044Higgins Michael J — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044PIERCE GLENN — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044GERAGHTY JAMES A — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-06-044SCANGOS GEORGE A — DirectorGrant/award (A): 24,000 (derivative) @ $0EDGAR
2025-04-044Ferguson Toby — Chief Medical OfficerSale (S): 10,086 @ $3.43EDGAR
2025-04-044Sandrock Alfred — President and CEO, DirectorSale (S): 10,885 @ $3.43EDGAR
2025-02-244Carter Todd Alfred — Chief Scientific OfficerSale (S): 3,305 @ $4.26 · Grant/award (A): 46,000 @ $0 · Grant/award (A): 92,000 (derivative) @ $0EDGAR
2025-02-244Swartz Robin — COO & CBOSale (S): 3,894 @ $4.25 · Grant/award (A): 71,250 @ $0 · Grant/award (A): 142,500 (derivative) @ $0EDGAR
2025-02-244Fahey Sandell Jacquelyn — Chief Legal OfficerGrant/award (A): 41,500 @ $0 · Grant/award (A): 83,000 (derivative) @ $0EDGAR
2025-02-244Ferguson Toby — Chief Medical OfficerGrant/award (A): 63,000 @ $0 · Grant/award (A): 126,000 (derivative) @ $0EDGAR
2025-02-244Jorgensen Nathan D. — Chief Financial OfficerGrant/award (A): 51,500 @ $0 · Grant/award (A): 103,000 (derivative) @ $0EDGAR
2025-02-244Sandrock Alfred — President and CEO, DirectorSale (S): 11,702 @ $4.24 · Grant/award (A): 145,000 @ $0 · Grant/award (A): 290,000 (derivative) @ $0EDGAR
2025-02-124Fahey Sandell Jacquelyn — Chief Legal OfficerSale (S): 4,358 @ $4.45EDGAR
2025-02-124Sandrock Alfred — President & CEOSale (S): 16,644 @ $4.45EDGAR

Recent 8-K events — Voyager Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-188-K/A2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-058-K2.01 — Completion of Acquisition or Disposition of AssetsEDGAR
2026-10-218-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-138-K8.01 — Other EventsEDGAR
2026-06-108-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-018-K8.01 — Other EventsEDGAR
2026-05-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-218-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-03-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=VYGR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs